{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Newer P2Y12 Inhibitors in ACS: Significant Reduction in Stent Thrombosis and Mortality - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"mpS0bq1AQS\"><a href=\"https:\/\/themedicalxchange.com\/en\/2014\/11\/25\/american-heart-association-aha-scientific-sessio-4\/\">Newer P2Y12 Inhibitors in ACS: Significant Reduction in Stent Thrombosis and Mortality<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2014\/11\/25\/american-heart-association-aha-scientific-sessio-4\/embed\/#?secret=mpS0bq1AQS\" width=\"600\" height=\"338\" title=\"&#8220;Newer P2Y12 Inhibitors in ACS: Significant Reduction in Stent Thrombosis and Mortality&#8221; &#8212; The Medical Xchange\" data-secret=\"mpS0bq1AQS\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7011_AHA_P2Y12_inhibitors_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Chicago \u2013 In a 12-month \u201creal world\u201d study of P2Y12 inhibitors in over 6500 ACS patients treated at a single centre, one agent was associated with lower stent thrombosis and mortality rates in all patients compared with two other agents in the study. The new findings suggest that treating these patients with this agent, instead of the previous standard treatment, could reduce the risks of stent thrombosis by 50%, which usually requires a repeat procedure or may even be fatal."}